Insense Ltd.

Revolutionary Healing Technology for Treating Difficult and Chronic Wounds Approved by Health Canada

    Toronto, Canada (ots/PRNewswire) - Archimed, the woundcare division of Insense Ltd., today announced it  has received approval from Health Canada for the use of its revolutionary  Oxyzyme product in the treatment of difficult and chronic wounds. Oxyzyme  was first trialed in Toronto by Dr. Gary Sibbald, one of the world's  leading wound care specialists, in 2004 by his team at the Toronto Wound Healing Centres. The announcement was made at the 3rd Congress of the World  Union of Wound Healing Societies taking place from June 4-8, 2008 at the  Metro Toronto Convention Center.

    Oxyzyme is a biochemical system in a dressing that ensures the oxygen  in the wound environment meets the diverse oxygen needs of the cells  responsible for healing. Ongoing clinical programs being undertaken in  Europe are showing that 20% of old, previously unhealable wounds (3.5 years ) are now closing in six weeks or under when dressed with Oxyzyme. Easy to  use by any clinical professional, Oxyzyme will now soon be available to the  Canadian health care system at a modest cost.

    In conjunction with the announcement, Professor T.K. Hunt, often cited  as the father of modern wound care, was awarded a lifetime achievement  award by the World Union of Wound Healing Societies. Professor Hunt's  insight and discoveries on the role oxygen plays in the healing process was  the inspiration behind the development of Oxyzyme.

    "The real value of Oxyzyme is that it combines two agents - iodine and  oxygen - that are essential to the process of wound healing and provides  further opportunities to overcome barriers to healing that may exist in the  patient," explained Dr. Keith Harding, leading figure in the international  wound care community and also a member of the World Union faculty.

    For more information about Oxyzyme and Archimed visit http://www.archimed.co.uk.

    About Insense Ltd.

    ------------------

    Insense is a British biotechnology company founded by Professor Paul  Davis, Chief Scientific Officer, who led the team which invented and  developed the ClearBlue(TM) pregnancy test. The company is also developing  products out of its core technology for dermatology and health and beauty  applications. For more information about Insense Ltd. visit www.insense.co.uk.

    For further information: Professor Paul Davis, Chief Scientific Officer , Founder, and Inventor, Paul.davis@insense.co.uk, +44-7825-983-216/

ots Originaltext: Insense Ltd.
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
For further information: Professor Paul Davis, Chief Scientific
Officer, Founder, and Inventor, Paul.davis@insense.co.uk,
+44-7825-983-216/



Das könnte Sie auch interessieren: